Mantle Cell Lymphoma
The latest news, research, and perspectives in mantle cell lymphoma (MCL). In MCL, a malignant B lymphocyte in the outer edge, or mantle zone, of a lymph node follicle grows uncontrollably, resulting in the accumulation of lymphoma cells.
Advertisement
Advertisement
Melody Smith, MD, MS, shares data on burnout in hematologist oncologists, why it occurs, and how to prevent it.
A panel moderated by Neil Love, MD, explored clinical data to assess these treatment approaches for the various types of NHL.
Clinical evaluations of this bispecific antibody as monotherapy or in polytherapy for B-cell non-Hodgkin lymphomas continue.
This new approval adds upon the agent's indications for relapsed or refractory DLBCL and other large B-cell lymphomas.
Dr. Phillips discussed the phase II TRIANGLE study, the shifting role of HSCT, and unmet needs in high-risk patients.
CAR22 therapy demonstrated an ORR of 100% and a complete response rate of 83% in six patients with MCL or FL.
Approved for adults ineligible for autologous transplant or CAR T-cell therapy following at least two systemic therapies.
David Russler-Germain, MD, PhD, joins the hosts of “Blood Cancer Talks” to highlight research in lymphoma and CLL.
Therapy also in development for T-cell acute lymphoblastic leukemia, chronic lymphocytic leukemia, and mantle cell lymphoma.
The single-slide test helps clinicians differentiate more than 60 subtypes of these diseases from normal immune response.
Researchers are launching a new clinical trial that will evaluate the combination of glofitamab with pirtobrutinib in MCL.
The therapies are under development for EBV-positive PTLD, non-Hodgkin lymphoma, and systemic lupus erythematosus.
Acalabrutinib was previously granted priority review in October 2024 based on results from the phase 3 ECHO trial.
Relmacabtagene autoleucel is an anti-CD19 chimeric antigen receptor T-cell product
Issues addressed include mandatory versus optional biopsy, informed consent, and safety in both adult and pediatric patients.
The phase 1b study of CAR22 is ongoing, and investigators are currently looking to enroll more patients.
A database study has identified an association between disease stage at lymphoma diagnosis and time of Medicaid enrollment.
Updated results from the phase 3 ECHO trial were presented at ASH 2024.
Future research must focus on developing more effective therapies to address the unmet needs of this high-risk MCL.
Results from the phase 1 ENABLE-1 study show complete responses comparable to commercial CAR Ts in B-cell NHL.
CTX112, a next-generation allogeneic CRISPR-Cas9–engineered showing encouraging results in B-cell malignancies.
Blood Cancers Today delivers the latest news, education, and information relevant to hematologic oncology patients and practices.
Sign up to receive Blood Cancers Today eNewsletters:
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.